{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.6"},{"groupId":"OG001","value":"25.9"},{"groupId":"OG002","value":"33.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"81"},{"groupId":"OG002","value":"60"}],"units":"Participants"}],"description":"CRR is the percentage of participants with complete remission as demonstrated by disappearance of all evidence of disease in the bone marrow, spleen, liver, and lymph nodes based on the IWG criteria using BICR. The analysis consisted of the point estimate and 95% 2-sided exact CI, separately by Cohort using the Clopper-Pearson method. Additional analyses were based on site assessment and by central review using the Lugano (2014) criteria.","groups":[{"description":"Participants with RRcHL who failed to achieve a response or progressed after auto-SCT and have relapsed after treatment with or failed to respond to BV post auto-SCT received pembrolizumab, 200 mg, intravenously (IV) every 3 weeks (Q3W) on Day 1 of each 21-day cycle up to 35 cycles, for up to 24 months.","id":"OG000","title":"Cohort 1"},{"description":"Participants with RRcHL who were unable to achieve Complete Response (CR) or Partial Response (PR) to salvage chemotherapy and did not receive auto-SCT, but have relapsed after treatment with or failed to respond to BV received pembrolizumab, 200 mg, IV Q3W on Day 1 of each 21-day cycle up to 35 cycles, for up to 24 months.","id":"OG001","title":"Cohort 2"},{"description":"Participants with RRcHL who failed to achieve a response to or progressed after auto-SCT and have not received BV post auto-SCT received pembrolizumab, 200 mg, IV Q3W on Day 1 of each 21-day cycle, up to 35 cycles for up to 24 months. These participants may or may not have received BV as part of primary treatment or salvage treatment.","id":"OG002","title":"Cohort 3"}],"paramType":"NUMBER","populationDescription":"All allocated participants who received at least 1 dose of study treatment.","reportingStatus":"POSTED","timeFrame":"Up to approximately 99 months","title":"Complete Remission Rate (CRR) by BICR Based on IWG Criteria","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}